Patients with low-grade serous carcinoma of the ovary or peritoneum (LGSC) developed chemoresistance to neoadjuvant platinum-based therapy.
An assay that measures tumor-derived cell-free DNA in plasma discriminated between patients with and without renal cell carcinoma with 99% accuracy.
Recent advances in cancer management may present challenges for nephrologists.
Combined with chemotherapy, venetoclax appears to be effective for treating AML among fit elderly patients.
This study examined the impact of a restructured prior authorization process on the delivery of PBT at a proton therapy center.
Patients treated with chemotherapy plus radiotherapy had a 64% reduced likelihood of disease progression or death compared with those who underwent chemotherapy alone.
The purpose of this study was to develop and test a gene-expression profiling assay to facilitate patient selection for induction chemotherapy in the setting of LA-NPC.
Standardized triage process significantly improved timeliness of diagnosis and staging of suspected lung cancer at a rapid assessment clinic.
In men with nonmetastatic castration-resistant prostate cancer, a PSA doubling time of less than 3 months vs 15 months or more increases the risk of metastasis, which in turn is associated with a large increase in healthcare utilization and costs.
Multiparametric magnetic resonance imaging is highly accurate in differentiating nonmuscle-invasive from muscle-invasive bladder cancer, according to a new systematic review and meta-analysis.
Increased odds of adverse outcomes seen for Hispanic/Latinos, African-American Blacks versus white patients.
A team of investigators conducted a multicenter cohort study to determine if a relationship existed between treatment for hyperthyroidism and risk of death from solid cancer.
A literature search of new studies clarifies, refutes, and expands on previous recommendations for managing new and established CIPN in patients treated with cytotoxic agents.
In a study, modified Glasgow prognostic score predicted nonorgan-confined disease and lymph node invasion at surgery.
CD30 CAR-T cell treatment after lymphodepletion may produce antitumor activity without significant toxicity in relapsed or refractory Hodgkin lymphoma.